Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neos Therapeutics (NEOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 319,000
  • Shares Outstanding, K 29,000
  • Annual Sales, $ 9,150 K
  • Annual Income, $ -83,330 K
  • 36-Month Beta -0.74
  • Price/Sales 11.44
  • Price/Cash Flow N/A
  • Price/Book 20.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.40 +17.82%
on 12/20/17
11.36 -2.49%
on 01/19/18
+1.43 (+14.77%)
since 12/19/17
3-Month
7.25 +52.76%
on 10/25/17
13.15 -15.78%
on 11/03/17
+3.57 (+47.67%)
since 10/19/17
52-Week
4.85 +128.35%
on 02/03/17
13.15 -15.78%
on 11/03/17
+5.17 (+87.71%)
since 01/19/17

Most Recent Stories

More News
Shares of Supernus Pharmac Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (SUPN, NEOS, IPXL, OCUL, BMY)

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

SUPN : 43.83 (+0.64%)
IPXL : 20.35 (-0.97%)
NEOS : 11.10 (+0.91%)
OCUL : 5.90 (+6.50%)
BMY : 61.88 (+0.08%)
Neos Therapeutics to Present Three Posters at the Upcoming American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release...

NEOS : 11.10 (+0.91%)
Free Research Reports on These Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Momenta Pharma, and Pacira Pharma

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on ADMS, NEOS, MNTA, and PCRX which is a click away at www.wallstequities.com/registration....

ADMS : 38.04 (+1.74%)
MNTA : 15.15 (-1.45%)
PCRX : 38.45 (-1.66%)
NEOS : 11.10 (+0.91%)
Neos Therapeutics to Participate in Two December Conferences

Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release...

NEOS : 11.10 (+0.91%)
Neos Therapeutics Reports Third Quarter 2017 Financial Results

Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release...

NEOS : 11.10 (+0.91%)
Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference

Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release...

NEOS : 11.10 (+0.91%)
Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017

Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release...

NEOS : 11.10 (+0.91%)
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, Inc. ("Neos") (NASDAQ: NEOS) Board of Directors' rejection of PDL's...

PDLI : 2.74 (-0.36%)
NEOS : 11.10 (+0.91%)
Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma

Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release...

PDLI : 2.74 (-0.36%)
NEOS : 11.10 (+0.91%)
Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma, and Collegium Pharma

If you want a Stock Review on ADMS, NEOS, ZYNE, or COLL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market today, DailyStockTracker.com observes...

COLL : 23.04 (+14.00%)
ADMS : 38.04 (+1.74%)
ZYNE : 11.33 (-0.87%)
NEOS : 11.10 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD;...

See More

Key Turning Points

2nd Resistance Point 11.47
1st Resistance Point 11.23
Last Price 11.10
1st Support Level 10.78
2nd Support Level 10.57

See More

52-Week High 13.15
Last Price 11.10
Fibonacci 61.8% 9.98
Fibonacci 50% 9.00
Fibonacci 38.2% 8.02
52-Week Low 4.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.